Osseon Therapeutics has entered into an agreement with DePuy Spine, for the distribution of its Osseoflex steerable spine augmentation needle throughout the US.
Osseoflex is a steerable, physician controlled vertebral compression fracture (VCF) needle that provides navigation within the vertebral body allowing pinpoint treatment for spinal disease and provides a minimally invasive treatment for VCFs, Osseon said.
Under the agreement, DePuy gains distribution rights in the US to sell Osseoflex alongside its Confidence Spinal Cement System directly through its sales network and Osseon will continue to maintain a direct sales force in strategic territories in the US and Europe.
Osseon president and chief executive officer John Stalcup said that the agreement allows Osseon to achieve even greater market penetration through DePuy’s extensive market presence and their highly regarded medical device sales organisation.
“We look forward to working with DePuy to significantly expand the availability of Osseoflex treatments for patients in the US,” Stalcup said.